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Abstract
Marijuana purchasing behaviors vary by the purchaser’s individual characteristics; however, little 
is known about patients’ purchasing behaviors when buying from medical marijuana dispensaries 
(MMDs). Our objective was to explore whether patient characteristics were associated with 
amount spent during one financial transaction at medical marijuana dispensaries. We conducted a 
pilot study of 4 purposively sampled MMD locations in Long Beach, California, in 2012. A total 
of 132 medical marijuana patients (33 patients per dispensary) participated in an exit survey about 
their demographic characteristics, conditions for their medical marijuana recommendation, amount 
spent at the dispensary, and cross-streets of where they lived. The sample reported amounts spent 
on discrete purchases of marijuana buds averaging $40.82 (ranging $10 to $255). Multivariate 
regression analyses indicated average amount spent differed significantly by patient age and 
condition. An increase in 10 years of age was associated with a 10% higher amount spent. 
Receiving a recommendation for anxiety and/or sleeping problems or other nonspecified 
conditions was related to higher discrete purchase amounts than chronic pain. This pilot suggests 
that variations in patient purchasing behaviors from MMDs exist. These purchase behaviors can 
provide insight into variations in how patients use dispensaries, consume products, and allocate 
personal resources.
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The line between licit and illicit marijuana use has become blurred in states such as 
California, which permit restricted medical use based on a physician recommendation and 
distribution via place-based venues. In 1996, California became the first state to permit use 
of marijuana to treat physician-identified, serious medical conditions (California 
Compassionate Use Act 1996). However, this law remained ambiguous as a result of the 
inclusion of diagnostic categories such as chronic pain and any other illness which 
marijuana provides relief. By 2003, MMDs were identified as legitimate distribution sources 
for medical marijuana by California law (Pacula & Sevigny 2014). In the context of medical 
marijuana dispensaries (MMDs) and associated laws, purchasing behaviors might identify 
those people who are by-passing traditional medical treatments, or in the case of 
nonsanctioned use, those who are at risk for abuse and dependence. Observed variation in 
purchasing behaviors by patient characteristics might indicate differential distribution of use 
behaviors and potential risks (e.g., cognitive impairments, marijuana abuse and dependence, 
unregulated sources of medication) that can be targeted for prevention and intervention 
(Lucas et al. 2013; Martín-Sánchez et al. 2009; Pacula et al. 2014).
Most of what we know of marijuana purchasing has been extrapolated from research on 
illicit markets. For example, larger total purchases in illicit marijuana markets were observed 
among men and non-Hispanic Whites (Caulkins & Pacula 2006). Considering the fact that 
illicit market purchase behaviors differ by demographics, medical marijuana purchase 
behaviors might differ by patient demographic characteristics as well. In fact, trends of 
medical marijuana patients in California from 2001 to 2012 parallel high-quantity 
purchasers identified in illicit markets, both being predominantly men, young adults, and 
non-Hispanic Whites (O’Connell & Bou-Matar 2007; Ryan-Ibarra, Induni & Ewing 2014).
Medical marijuana purchases may also differ by the diagnosis for which patients receive 
their recommendations. Patients have primarily reported medical conditions of chronic pain, 
sleeping problems, and anxiety (O’Connell & Bou-Matar 2007; Ryan-Ibarra et al. 2014). 
Among these patients, it is possible that including chronic pain as a qualifying condition for 
marijuana could have variable influences on effects of medical marijuana recommendation 
and distribution policies (Pacula et al. 2015). For example, if chronic pain is actually a 
“catch all” diagnosis for medical marijuana that allows doctors to provide recommendations 
for virtually any pain, it may allow nonmedical users to exploit the law for recreational use. 
The extent to which they spend different amounts on a purchase compared with those 
addressing a more serious terminal condition (e.g., cancer) may provide information on 
patterns of use. Finally, the buyer’s distance from an MMD might influence purchasing 
behaviors (Caulkins & Pacula 2006; Pacula et al. 2010). For instance, patients who live 
farther from the dispensary might spend more at one given time (by purchasing higher 
amounts of product) because it is less convenient to access the dispensary often for smaller 
amounts compared with a patient who lives closer.
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This pilot study aimed to assess whether variation in purchasing behaviors by patient 
characteristics was present among individuals who purchased medical marijuana from 
dispensaries in Long Beach, California, in 2012. We explored how patient characteristics 
specific to demographics, medical condition for medical marijuana recommendation, and 
distance traveled were associated with individuals’ amount spent on marijuana buds during 
one financial transaction.
Method
Study Design and Sampling Procedures
The pilot study purposively sampled four MMD locations in Long Beach, California, in 
2012. This sampling approach allowed us to capture variation in MMDs specific to their 
geographic location, size, and patient demographics. Patients were asked to participate in the 
survey as they exited the dispensaries. Data were collected via portable handheld devices, 
and survey workers obtained verbal informed consent. The survey included questions about 
respondents’ demographic characteristics, medical conditions, amount spent on marijuana 
buds only on that particular visit to the dispensary, and cross-streets of where they lived. 
Respondents received a $20 cash incentive to participate in a 5-minute survey with the hope 
of engaging them in completing a longer, online survey for additional compensation; this 
amount is commensurate with other venue-based surveys (Miller et al. 2005). A total of 132 
patients (33 patients per dispensary) agreed to complete the survey from the 166 patients 
who were approached. The incentive rate resulted in a high initial response rate (79.5%), but 
the conversion rate to the online survey was low (approximately 20%).
Data collection occurred during one day at each dispensary, with a morning shift from 10 
a.m. to 1 p.m. and an afternoon shift from 2 p.m. to 5 p.m. Assessment of sample bias 
between respondents and nonrespondents indicated that nonrespondents were significantly 
more likely to be male (χ2 = 4.79, p = 0.029). No difference was observed in demographic 
characteristics based on time of day of the survey. Study protocols were approved by the 
University of California, Los Angeles’ Institutional Review Board.
Measures
The dependent variable for the study was amount spent to purchase marijuana buds only, 
given that the vast majority of the sample (92%) reported purchasing only marijuana buds 
(as opposed to concentrates and edibles). The dependent variable was defined as a ratio scale 
of dollar amounts with patient reports ranging from $10 to $255. Independent variables 
included age, gender, race/ethnicity, condition for which medical marijuana recommendation 
was originally obtained, and distance from home address to the dispensary where the survey 
occurred. Respondents could specify more than one condition for medical marijuana 
recommendation, and those conditions were categorized into four mutually exclusive 
categories: specific medical conditions, anxiety and/or sleeping problems, chronic pain, and 
other nonspecified conditions. Specific medical conditions included anorexia, arthritis, 
Crohn’s disease, glaucoma, HIV/AIDS, multiple sclerosis, and migraines. Anxiety and sleep 
problems (that did not co-occur with a specific medical condition) were combined into one 
category, given the high prevalence of sleep disturbances and anxiety disorders co-occurring 
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(Staner 2003). Chronic pain included respondents who reported chronic pain without any 
other reported specific medical conditions, anxiety, and/or sleep problems. Other 
nonspecified conditions included respondents who reported “other condition” on the survey 
without any further specification and who did not identify any of the prior categories for 
their medical marijuana recommendation. To account for multiple conditions, a count of the 
total number of conditions reported was included.
To measure distance, straight line distance to each dispensary was calculated by asking 
participants for the nearest cross street to their home address. Twelve out of 132 cross streets 
(9.1%) were unable to be geocoded because the streets reported could not be found in 
ArcGIS or on Google Maps. This variable was dichotomized into respondents residing 
within 1 mile and those residing greater than 1 mile of the dispensary, because of the right-
skewed distribution of this variable. One mile was chosen as a cut-off to capture respondents 
that were more likely to reside within walking or a short driving distance from the utilized 
dispensary.
Data Analysis
Descriptive statistics were reported for age, race, gender, condition for medical marijuana 
recommendation, purchase amount, and residence proximity to the dispensary for the whole 
sample (n = 132). Bivariate comparisons (i.e., t tests, F tests, and Pearson’s correlations) 
were used to assess whether demographic characteristics, including age, gender, race, 
medical condition, and patient proximity to their respective dispensaries were related to 
purchase amount. We used multivariate linear regression to examine whether these patient 
characteristics were correlated with purchase amount. Purchase amount was log transformed 
to address the skewed distribution of the continuous dependent variable resulting from the 
presence of an outlier. Given the small number of dispensaries sampled for the exit survey (n 
= 4), we controlled for patients clustering within dispensary locations by including 
individual level vectors for the dispensary at which the patient was surveyed (Newman & 
Newman 2012; Raudenbush & Bryk 2002).
The final analytic sample used in the bivariate comparisons and multivariate linear 
regressions was composed of 106 patients with complete information. We observed no 
significant differences between patients with (n = 106) and without (n = 26) complete 
information for any of the study variables. Finally, regression coefficients from the 
multivariate analyses were exponentiated to discuss percent difference in amount spent on a 
discrete purchase.
Results
Table 1 details characteristics for the full sample. Descriptive analyses indicated that the 
majority of patients in our study were male, about 30 years of age, and of different races. 
The average discrete purchase for marijuana buds was $40.82 (with a range of $10 to $255). 
At the time of the study, the $40 average purchase price was likely indicative of a purchase 
of 1/8 ounce of marijuana, which was a typical amount for these dispensaries; the upper 
range value of $255 is akin to amounts needed to purchase a full ounce of marijuana. 
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Residence straight-line distance from the dispensary locations averaged 3.91 miles, with a 
range from 0.03 to 22.05 miles.
Results from bivariate comparisons indicated race/ethnicity (F(3, 102) = 4.04, p = .009), 
condition for medical marijuana recommendation (F(3, 102) = 3.34, p = .022), number of 
conditions reported (r(104) = .27, p = .005), and residence within 1 mile the MMD (t(104) = 
2.48, p = .015) were all significantly associated with discrete purchase amount of medical 
marijuana buds. No significant bivariate relationships were observed for age (r(104) = .18, p 
= .069) or gender (t(104) = −0.51, p = .610).
Table 2 displays the results from the multivariate regressions. Model 1 included all patient 
demographic variables, and Model 2 shows the full model that included patient 
demographics, primary conditions for medical marijuana recommendation, and proximity of 
residence to the MMD. A nested F test indicated the block for medical conditions and 
proximity significantly added to the explained variance of the model.
The subsequent text describes the percentage change or difference obtained by the 
exponentiation of the regression coefficients reported in Table 2, Model 2. When controlling 
for all other variables in the full model, discrete purchase of marijuana buds increased 1% on 
average for every increase in 1 year of age. For example, an MMD patient who reported 
being 45 years old spent 20% more on average for a discrete purchase of marijuana buds 
compared with an MMD patient who reported being 25 years old. In addition, the average 
purchase amount for patients obtaining marijuana through a recommendation to treat anxiety 
and/or sleep problems was 48% higher than for those obtaining marijuana through a 
recommendation to treat chronic pain. Patients reporting a recommendation primarily for 
any other condition (nonspecified) were associated with a 54% higher average purchase 
amount for marijuana buds than those reporting a recommendation primarily for chronic 
pain. No significant relationship was observed between proximity of patient residence to the 
MMD and discrete purchase amount.
Discussion
This pilot study suggests that variation in purchase behaviors may be associated with patient 
characteristics. Demographic characteristics related to sex and age were consistent with 
other studies, suggesting venue-based clients are overwhelmingly young adults and male 
(Grella & Rodriguez 2014; Nunberg et al. 2011; Reiman 2007; Reinarman et al. 2011). 
However, the current sample was more diverse than that in prior studies, which found that 
more than 50% of medical marijuana users and MMD clients identified as non-Hispanic 
White (O’Connell & Bou-Matar 2007; Nunberg et al. 2011; Reiman 2007; Reinarman et al. 
2011; Ryan-Ibarra et al. 2014). Age was positively associated with discrete purchase 
amounts, suggesting that that older clients spend more on average at a given time, which 
may be indicative of higher consumption of and/or higher concentration of THC within 
products. However, age may also be acting as a proxy for higher income among older 
clients. This finding could also arise from younger clients spending less with more frequent 
visits or spending less on marijuana buds and more on other types of products such as 
edibles and tinctures compared with older clients.
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Client reports of medical conditions associated with receiving a medical marijuana 
recommendation are consistent with both physical and mental health issues observed in prior 
studies (e.g., Grella & Rodriguez 2014; Reiman 2007). Higher amounts were spent by 
patients with recommendations for anxiety and/or sleep problems compared with chronic 
pain. The higher purchase amounts by patients reporting anxiety or sleeping problems might 
result in MMDs focusing on marketing to patrons with these conditions (Gruenewald 2007), 
which is concerning given evidence supporting marijuana withdrawal exacerbating these 
conditions (e.g., Budney & Hughes 2006; Haney et al. 1999). Patients suffering from anxiety 
may also consume marijuana in larger amounts as a social lubricating mechanism or to 
alleviate withdrawal symptoms, increasing the risk for developing abuse and dependence. In 
addition, patients reporting a recommendation for other, nonspecified conditions were 
associated with a higher discrete purchase amount compared with patients reporting a 
recommendation for chronic pain. Given that these conditions might not fall into categories 
originally intended for medical marijuana use, this category of patients could be composed 
of medical marijuana users with a higher proportion of nonsanctioned use and at higher risk 
for abuse and dependence.
Findings should be considered in context of study limitations. First, the study used a 
nonrandom sample of four dispensaries and collected data from a small sample of patients. 
Statistical power is limited in the current study. Although the current study distinguished 
between the most predominant medical conditions associated with medical marijuana use 
(i.e., specific medical conditions, chronic pain, anxiety, sleep problems; Reinarman et al. 
2011), future studies should evaluate both recommended conditions and standardized 
measures of respondent’s current health. This information would provide insight into 
purchase behaviors associated with sanctioned and nonsanctioned use. Finally, limited 
information can be derived from total discrete purchase amount alone. Future studies should 
refine measures to include price per ounce, total amount of product purchased, variation in 
potency, and number of discrete purchases over time (Caulkins & Pacula 2006; Sevigny, 
Pacula, & Heaton 2014). These refinements are important given the preliminary findings that 
medical marijuana laws, including legitimization of MMDs, were associated with increased 
potency and decreased prices of a high potency product (Pacula et al. 2010; Sevigny et al. 
2014). The types of strains purchased may also provide some information about the match 
between the condition of referral and known ability of the strain to address those conditions.
This pilot study offers an avenue of research on legal marijuana outlets that moves beyond 
the study of patient demographics. Economic factors, such as purchasing decisions and 
behaviors, provide insight into how individuals are obtaining and possibly consuming 
marijuana products sold from this newer type of drug outlet. Future research can begin to 
explore whether larger purchases contribute to higher consumption and/or a higher 
concentration of THC associated with psychotropic effects and adverse outcomes (Harder & 
Rietbrock 1997). In addition, there is a great potential for diversion with larger purchase 
amounts. While small purchase amounts are more likely to be consumed immediately, larger 
purchase amounts are more likely to result in left-over marijuana products that can be sold 
or given to individuals who do not have a recommendation or are underage (Salomonsen-
Sautel, et al. 2012; Reinarman et al. 2011; Caulkins 2005).
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Recent evidence suggests a shift in the California medical marijuana population toward 
more patients reporting medical marijuana use for anxiety and/or insomnia (Nunberg et al. 
2011; Reinarman et al. 2011). More information regarding purchasing behavior can help 
policy makers understand the consumption patterns and needs of this growing subpopulation 
of medical marijuana users. For patients who report substituting marijuana use for traditional 
prescription medication (Nunberg et al. 2011; Reinarman et al. 2011), understanding how 
economic factors (e.g., cost and lack of insurance) might contribute to this choice could 
provide insight into identifying the best treatment options for a patient. Physicians might 
need to explore a client’s motivation for medical marijuana use in relation to effectiveness, 
adverse effects, and cost in relation to other available treatment options.
Future studies could help to clarify whether observed differences in purchasing behaviors 
are due to medical versus nonsanctioned use of marijuana. If larger purchase amounts are 
being driven by nonsanctioned use, research should explore the implications of marijuana 
access and potential for abuse behaviors in states where legal venues (both medical and 
recreational) are present. In addition, understanding how purchasing behaviors are 
associated with physical and psychological consequences of use can help policy makers and 
interventionists to identify whether policy-level prevention strategies are effective in 
minimizing potential adverse consequences, as are observed with alcohol outlets (Wagenaar, 
Salois, & Komro 2009).
In sum, the findings from this pilot study suggest the value of exploring economic factors 
and their interplay with patient characteristics. Purchase behaviors can provide insight into 
variations in how patients use dispensaries, consume products, and allocate personal 
resources. These data could allow clinicians, policy makers, and researchers to make more 
informed decisions about the use of medical marijuana and their distributors based on a 
better understanding of how individuals are using these newer drug outlets and being 
affected by consumption of their products.
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Table 1
Characteristics of Participants Recruited at Four Medical Marijuana Dispensaries (N =132)
Sample n % or x̄ (sd) Min Max
Purchase amount (dollars) 117 40.82 (33.89) 10.00 255.00
Age (years) 132 30.46 (12.01) 18.00 76.00
Gender
 Male 97 73.48
 Female 35 26.52
Race/Ethnicity
 Non-Hispanic White 34 25.75
 Non-Hispanic Black 41 31.06
 Latino 43 32.58
 Other, including Asian 14 10.61
Condition for medical marijuana recommendation
 Specific physical illness 33 25.19
 Anxiety and/or sleep problems 44 33.59
 Chronic pain 32 24.43
 Other nonspecified condition 22 16.79
Number of conditions 131 1.62 1.00 4.00
Resident’s distance from MMD (miles) 120 3.91 (4.53) 0.03 22.05
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Table 2
Log of Purchase Amount Regressed on Respondent Characteristics, Condition for Medical Marijuana 
Recommendation, and Proximity to MMD (n = 106)
Variables
Model 1 Model 2
b (SE) p b (SE) p
Constant 3.35 (0.34) < .001 2.58 (0.39) < .001
Sampling location (ref: MMD 1)
 MMD 2 0.00 (0.20) .997 −0.05 (0.20) .811
 MMD 3 −0.26 (0.19) .175 −0.11 (0.20) .578
 MMD 4 −0.17 (0.19) .393 −0.08 (0.19) .678
Age (years) 0.01 (0.01) .088 0.01 (0.01) .036
Male (ref: female) 0.15 (0.16) .469 0.21 (0.16) .189
Race/ethnicity (ref: White)
 Latino −0.21 (0.19) .265 −0.09 (0.20) .646
 Black −0.49 (0.18) .021 −0.27 (0.18) .146
 Other race 0.12 (0.25) .648 0.01 (0.25) .963
Condition for medical marijuana recommendation (ref: chronic pain)
 Specific physical illness 0.11 (0.21) .613
 Anxiety and/or sleep problems 0.39 (0.20) .049
 Other condition 0.43 (0.21) .042
Number of conditions 0.21 (0.11) .058
Residence within 1 mile of MMD −0.27 (0.16) .101
R2 .16 .28
Nested F Test 3.00 .015
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